|
Back to Home » December 2020 News » AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL) |
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL) |
December 06, 2020
NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA®/VENCLYXTO® (venetoclax) fixed duration treatment combinations at the virtual 62nd American Society of...
Source URL: http://prnmedia.prnewswire.com/news-releases/abbvie-presents-extended-follow-up-data-for-fixed-duration-treatment-venclextavenclyxto-venetoclax-in-chronic-lymphocytic-leukemia-cll-301186833.html
|
|
|
|
